Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study-Reference-Cited by-同舟云学术

Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study

Published:2013-03 Issue:1-2 Volume:326 Page:10-17
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Holland Starr,Fanning Kristina M.,Serrano Daniel,Buse Dawn C.,Reed Michael L.,Lipton Richard B.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference15 articles.

1. Prevalence and burden of migraine in the United States: data from the American Migraine Study II;Lipton;Headache,2001

2. Migraine prevalence, disease burden, and the need for preventive therapy;Lipton;Neurology,2007

3. Acute medication use patterns in episodic migraine: results of the American Migraine Prevalence and Prevention Study (AMPP);Lipton;Cephalalgia,2009

4. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study;Chu;Headache,2012

5. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention study;Bigal;Headache,2010

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial;Neurology;2024-07-23

2. Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK;Journal of Medical Economics;2024-04-27

3. Medication “underuse” headache;Cephalalgia;2024-04

4. Characterizing opioid use in a Dutch cohort with migraine;Cephalalgia;2023-05

5. Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine;Headache: The Journal of Head and Face Pain;2023-02-07